Market Uptake Of New Incontinence Agents Impeded By Efficacy Perceptions, Novartis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Public may view new overactive bladder treatments, such as Novartis' Enablex, as lacking efficacy advantages, according to the company.
You may also be interested in...
Sanctura XR Could Quench Indevus’ Thirst For Once-Daily Incontinence Therapy
Results from the first of two Phase III trials of trospium extended-release report 8.7% incidence of dry mouth, compared to 20.1% for twice-daily Sanctura.
Lipitor Pricing Offsets Loss In Prescription Volume, Pfizer Says
Declines in Lipitor's prescription volume due to the presence of generic simvastatin are being offset by price increases, Pfizer says